Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS
· Delayed Price · Currency is USD
1.990
-0.100 (-4.78%)
Feb 21, 2025, 3:52 PM EST
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $29.99M in the quarter ending December 31, 2024, with 18.96% growth. This brings the company's revenue in the last twelve months to $109.54M, down -5.34% year-over-year. In the fiscal year ending March 31, 2024, Medexus Pharmaceuticals had annual revenue of $113.05M with 4.59% growth.
Revenue (ttm)
109.54M
Revenue Growth
-5.34%
P/S Ratio
n/a
Revenue / Employee
1.34M
Employees
82
Market Cap
65.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
Mar 31, 2020 | 55.51M | 21.64M | 63.91% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |
Medexus Pharmaceuticals News
- 16 days ago - Medexus Pharmaceuticals, Inc. (MEDXF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States - Newsfile Corp
- 19 days ago - Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada - Newsfile Corp
- 22 days ago - Medexus Schedules Third Fiscal Quarter 2025 Conference Call - Newsfile Corp
- 22 days ago - Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares - Newsfile Corp
- 25 days ago - Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares - GlobeNewsWire
- 26 days ago - Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares - GlobeNewsWire
- 4 weeks ago - Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update - Newsfile Corp